Edition:
India

Zhangzhou Pientzehuang Pharmaceutical Ltd (600436.SS)

600436.SS on Shanghai Stock Exchange

74.95CNY
12:29pm IST
Change (% chg)

¥2.01 (+2.76%)
Prev Close
¥72.94
Open
¥72.72
Day's High
¥76.00
Day's Low
¥71.77
Volume
7,701,334
Avg. Vol
5,927,050
52-wk High
¥76.00
52-wk Low
¥43.90

Chart for

About

ZHANGZHOUPIENTZEHUANG PHARMACEUTICAL .LTD is a China-based company principally engaged in pharmaceutical production and distribution business. The Company's major products include Pientzehuang series for pain-inhibition, anti-inflammation, detoxification and curing hepatitis, tablets for coronary heart diseases and hypertension,... (more)

Overall

Beta: 0.85
Market Cap(Mil.): ¥35,149.26
Shares Outstanding(Mil.): 603.32
Dividend: 0.27
Yield (%): 0.46

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Zhangzhou Pientzehuang Pharmaceutical Sees 2017 Net Profit Up 40-60 Percent Y/Y

Jan 9 Zhangzhou Pientzehuang Pharmaceutical Ltd :

09 Jan 2018

BRIEF-Zhangzhou Pientzehuang Pharmaceutical passes review of high-tech enterprise recognition

* Says it passed the review of high-tech enterprise recognition and will enjoy a tax preference of 15 percent for three years since 2017

04 Jan 2018

BRIEF-Zhangzhou Pientzehuang Pharma's 9-month net profit up 40.3 pct y/y

Oct 26 Zhangzhou Pientzehuang Pharmaceutical Ltd * Says 9-month net profit up 40.3 percent y/y Source text in Chinese: http://bit.ly/2z9PX5m Further company coverage: (Reporting by Hong Kong newsroom)

26 Oct 2017

BRIEF-Zhangzhou Pientzehuang Pharmaceutical elects Liu Jianshun as chairman

Sept 25 Zhangzhou Pientzehuang Pharmaceutical Ltd

25 Sep 2017

BRIEF-Zhangzhou Pientzehuang Pharmaceutical's H1 net profit up 41.8 pct y/y

Aug 24 Zhangzhou Pientzehuang Pharmaceutical Co Ltd

24 Aug 2017

BRIEF-Zhangzhou Pientzehuang Pharmaceutical's preliminary H1 net profit up 41.9 pct y/y

* Says prelim H1 net profit up 41.9 percent y/y at 433.3 million yuan ($64.01 million)

17 Jul 2017

Earnings vs. Estimates